Elicera Therapeutics’ Chief Scientific Officer, Professor Magnus Essand, to present at SWECARNET’s Educational Day 2022
Gothenburg, February 24, 2022 - Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company that develops next generation immuno-oncological treatments based on enhanced oncolytic viruses and CAR T-cells, today announced that the company’s Chief Scientific Officer (CSO) and co-founder, Professor Magnus Essand, will present at SWECARNET’s Educational Day on April 27[th], 2022.SWECARNET, Sweden’s network for clinical use of CAR T-cells, will hold an Educational Day on April 27[th], 2022, where Elicera’s CSO, Professor Magnus Essand, will hold a presentation on